Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Alexander MacKinnon

Anatomic Pathology Birmingham, AL Medical Doctor

NPI 1710214820 CMS profile 611090

619 19Th St S, Birmingham, AL 35249

Open in the dashboard

General payments

$3,019

15 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Alexander MacKinnon of Birmingham, AL is reported in the CMS Open Payments database as having received $3,019 across 15 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Anatomic Pathology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $203 2
2023 General $1,396 3
2022 General $1,347 9
2019 General $73 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Alexander MacKinnon
  • Anatomic Pathology median
  • Middle half of Anatomic Pathology
  • National median

In program year 2025, general payments to Alexander MacKinnon were reported at $203. Among 419 Anatomic Pathology profiles paid that year, the median was $110 and the middle half received between $28 and $974.

Show as a table
Year Alexander MacKinnon Anatomic Pathology median Middle half National median
2019 $73 $112 $31–$404 $163
2020 $0 $185 $25–$4,265 $114
2021 $0 $121 $24–$2,629 $132
2022 $1,347 $121 $31–$1,816 $149
2023 $1,396 $96 $28–$1,008 $160
2024 $0 $103 $28–$1,069 $164
2025 $203 $110 $28–$974 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Illumina, Inc. $1,288 6 payments
  2. Eli Lilly and Company $1,150 1 payment
  3. Laboratory Corporation of America Holdings $215 1 payment
  4. Personal Genome Diagnostics Inc $181 1 payment
  5. Roche Molecular Systems, Inc. $73 1 payment
  6. Merck Sharp & Dohme Corporation $65 3 payments
  7. AstraZeneca Pharmaceuticals LP $46 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,275 12 payments
  2. Consulting Fee $1,150 1 payment
  3. Gift $581 1 payment
  4. Entertainment $13 1 payment
Products named General payments · program years 2019–2025
  1. NovaSeq 6000Dx Sequencer Instrument $1,288 6 payments
  2. PGDX ELIO TISSUE COMPLETE $396 2 payments
  3. DIAGNOSTICS INFORMATION SYSTEMS $73 1 payment
  4. KEYTRUDA $65 3 payments
  5. LYNPARZA Oncology $65 3 payments
  6. LYNPARZA Oncology $32 1 payment
  7. TAGRISSO $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$8,842

Medicare's payments for the services billed

Medicare patients

243

Average age 72

Services billed

307

132 women, 111 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Chronic kidney disease 42%
Diabetes 40%
Cancer 37%
Ischemic heart disease 36%
Depression 29%
Heart failure 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

15 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Anatomic Pathology in Alabama

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record